Wire · ai
IQV Q2 Deep Dive: Broad-Based Growth and AI-Driven Momentum Across Segments
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 29 July 2026 · Fusion42 review
Clinical research organisation IQVIA reported strong Q2 growth, with revenue up 8.7% YoY to $4.37 billion, driven by an acceleration in outsourcing from pharmaceutical clients and the adoption of its AI tools. The company highlighted that AI is enhancing clinical trial design and patient recruitment, leading to higher win rates against competitors.
This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.
◆ ◆ The Wire takeaway
AI for clinical trials is no longer a niche startup pitch; it's the incumbent's new standard. Pharma clients now expect AI-driven efficiency for study design and recruitment, meaning your tech must now compete with the scale and data of players like IQVIA.
◆ Coverage
1 source · 29 Jul 2026
◆ Related on Wire
◆ Topics